Cargando…
Future directions of neoadjuvant therapy in pancreatic cancer
Neoadjuvant therapy with conventional chemotherapies have visibly improved the prognosis of locally advanced pancreatic cancer (PCa). However, molecular targeted therapies that have provided durable responses in other tumor entities, have not yet found access into neoadjuvant therapy of PCa. In fact...
Autores principales: | Mota Reyes, Carmen, Yurteri, Ümmügülsüm, Friess, Helmut, Ekin Demir, Ihsan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7458337/ https://www.ncbi.nlm.nih.gov/pubmed/32923514 http://dx.doi.org/10.18632/oncoscience.506 |
Ejemplares similares
-
Neoadjuvant therapy in pancreatic cancer: what is the true oncological benefit?
por: Ren, Lei, et al.
Publicado: (2020) -
Innervated mouse pancreas organoids as an ex vivo model to study pancreatic neuropathy in pancreatic cancer
por: Besikcioglu, H. Erdinc, et al.
Publicado: (2021) -
Regulatory T Cells in Pancreatic Cancer: Of Mice and Men
por: Mota Reyes, Carmen, et al.
Publicado: (2022) -
Pancreatic cancer — lessons from the past decade
por: Demir, Ihsan Ekin, et al.
Publicado: (2015) -
Nerve-Cancer Interactions in the Stromal Biology of Pancreatic Cancer
por: Demir, Ihsan Ekin, et al.
Publicado: (2012)